Fig. 2From: Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)Changes from baseline in the mean SBP/DBP at month 3, 6, 9, and 12 after olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) administration. Effectiveness set (n = 3052). BP, blood pressure; SBP, systolic BP; DBP, diastolic BP. *P < 0.0001 (Wilcoxon singed-rank test)Back to article page